A clinical trial (NCT04101851) has just commenced evaluating whether it is oncologically safe to omit SLNB in triple-negative and HER2-positive breast cancer patients with radiologic and pathological complete response in the breast after NST [38]. The gene discussed is ERBB2; the disease is breast cancer.